The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise, ethnicity (African American men), and old age contribute to its occurrence.
The global Prostate Cancer Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Medicine.
Report Scope
The Prostate Cancer Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prostate Cancer Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prostate Cancer Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
- AstraZeneca plc
- Active Biotech
- Bristol Myers-Squibb
- Teva Pharmaceuticals Industries Ltd.
- Johnson & Johnson
- Pfizer Inc.
- Bayer AG
- Abbott Laboratories
- Astellas Pharma Inc.
- Roche Holding AG
Segment by Type
- LHRH Antagonists
- LHRH Analogs
- Antiandrogens
- Pipeline Drugs for Hormonal Therapy
Segment by Application
- Age Below 55
- Age 55-75
- Age Above 75
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Cancer Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prostate Cancer Medicine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 LHRH Antagonists
1.2.3 LHRH Analogs
1.2.4 Antiandrogens
1.2.5 Pipeline Drugs for Hormonal Therapy
1.3 Market by Application
1.3.1 Global Prostate Cancer Medicine Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Age Below 55
1.3.3 Age 55-75
1.3.4 Age Above 75
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Medicine Market Perspective (2019-2030)
2.2 Prostate Cancer Medicine Growth Trends by Region
2.2.1 Global Prostate Cancer Medicine Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Prostate Cancer Medicine Historic Market Size by Region (2019-2024)
2.2.3 Prostate Cancer Medicine Forecasted Market Size by Region (2025-2030)
2.3 Prostate Cancer Medicine Market Dynamics
2.3.1 Prostate Cancer Medicine Industry Trends
2.3.2 Prostate Cancer Medicine Market Drivers
2.3.3 Prostate Cancer Medicine Market Challenges
2.3.4 Prostate Cancer Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Medicine Players by Revenue
3.1.1 Global Top Prostate Cancer Medicine Players by Revenue (2019-2024)
3.1.2 Global Prostate Cancer Medicine Revenue Market Share by Players (2019-2024)
3.2 Global Prostate Cancer Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Cancer Medicine Revenue
3.4 Global Prostate Cancer Medicine Market Concentration Ratio
3.4.1 Global Prostate Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Medicine Revenue in 2023
3.5 Prostate Cancer Medicine Key Players Head office and Area Served
3.6 Key Players Prostate Cancer Medicine Product Solution and Service
3.7 Date of Enter into Prostate Cancer Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Medicine Breakdown Data by Type
4.1 Global Prostate Cancer Medicine Historic Market Size by Type (2019-2024)
4.2 Global Prostate Cancer Medicine Forecasted Market Size by Type (2025-2030)
5 Prostate Cancer Medicine Breakdown Data by Application
5.1 Global Prostate Cancer Medicine Historic Market Size by Application (2019-2024)
5.2 Global Prostate Cancer Medicine Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Prostate Cancer Medicine Market Size (2019-2030)
6.2 North America Prostate Cancer Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Prostate Cancer Medicine Market Size by Country (2019-2024)
6.4 North America Prostate Cancer Medicine Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prostate Cancer Medicine Market Size (2019-2030)
7.2 Europe Prostate Cancer Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Prostate Cancer Medicine Market Size by Country (2019-2024)
7.4 Europe Prostate Cancer Medicine Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Medicine Market Size (2019-2030)
8.2 Asia-Pacific Prostate Cancer Medicine Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Prostate Cancer Medicine Market Size by Region (2019-2024)
8.4 Asia-Pacific Prostate Cancer Medicine Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prostate Cancer Medicine Market Size (2019-2030)
9.2 Latin America Prostate Cancer Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Prostate Cancer Medicine Market Size by Country (2019-2024)
9.4 Latin America Prostate Cancer Medicine Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Medicine Market Size (2019-2030)
10.2 Middle East & Africa Prostate Cancer Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Prostate Cancer Medicine Market Size by Country (2019-2024)
10.4 Middle East & Africa Prostate Cancer Medicine Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca plc
11.1.1 AstraZeneca plc Company Detail
11.1.2 AstraZeneca plc Business Overview
11.1.3 AstraZeneca plc Prostate Cancer Medicine Introduction
11.1.4 AstraZeneca plc Revenue in Prostate Cancer Medicine Business (2019-2024)
11.1.5 AstraZeneca plc Recent Development
11.2 Active Biotech
11.2.1 Active Biotech Company Detail
11.2.2 Active Biotech Business Overview
11.2.3 Active Biotech Prostate Cancer Medicine Introduction
11.2.4 Active Biotech Revenue in Prostate Cancer Medicine Business (2019-2024)
11.2.5 Active Biotech Recent Development
11.3 Bristol Myers-Squibb
11.3.1 Bristol Myers-Squibb Company Detail
11.3.2 Bristol Myers-Squibb Business Overview
11.3.3 Bristol Myers-Squibb Prostate Cancer Medicine Introduction
11.3.4 Bristol Myers-Squibb Revenue in Prostate Cancer Medicine Business (2019-2024)
11.3.5 Bristol Myers-Squibb Recent Development
11.4 Teva Pharmaceuticals Industries Ltd.
11.4.1 Teva Pharmaceuticals Industries Ltd. Company Detail
11.4.2 Teva Pharmaceuticals Industries Ltd. Business Overview
11.4.3 Teva Pharmaceuticals Industries Ltd. Prostate Cancer Medicine Introduction
11.4.4 Teva Pharmaceuticals Industries Ltd. Revenue in Prostate Cancer Medicine Business (2019-2024)
11.4.5 Teva Pharmaceuticals Industries Ltd. Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Prostate Cancer Medicine Introduction
11.5.4 Johnson & Johnson Revenue in Prostate Cancer Medicine Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer Inc.
11.6.1 Pfizer Inc. Company Detail
11.6.2 Pfizer Inc. Business Overview
11.6.3 Pfizer Inc. Prostate Cancer Medicine Introduction
11.6.4 Pfizer Inc. Revenue in Prostate Cancer Medicine Business (2019-2024)
11.6.5 Pfizer Inc. Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Prostate Cancer Medicine Introduction
11.7.4 Bayer AG Revenue in Prostate Cancer Medicine Business (2019-2024)
11.7.5 Bayer AG Recent Development
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Detail
11.8.2 Abbott Laboratories Business Overview
11.8.3 Abbott Laboratories Prostate Cancer Medicine Introduction
11.8.4 Abbott Laboratories Revenue in Prostate Cancer Medicine Business (2019-2024)
11.8.5 Abbott Laboratories Recent Development
11.9 Astellas Pharma Inc.
11.9.1 Astellas Pharma Inc. Company Detail
11.9.2 Astellas Pharma Inc. Business Overview
11.9.3 Astellas Pharma Inc. Prostate Cancer Medicine Introduction
11.9.4 Astellas Pharma Inc. Revenue in Prostate Cancer Medicine Business (2019-2024)
11.9.5 Astellas Pharma Inc. Recent Development
11.10 Roche Holding AG
11.10.1 Roche Holding AG Company Detail
11.10.2 Roche Holding AG Business Overview
11.10.3 Roche Holding AG Prostate Cancer Medicine Introduction
11.10.4 Roche Holding AG Revenue in Prostate Cancer Medicine Business (2019-2024)
11.10.5 Roche Holding AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
